CREM Co Labs’ scientists are attending Canadian Society for Pharmaceutical Sciences (CSPS) Symposium 2023 taking place at Metro Toronto Convention Center from May 24th to May 26th.
“The Symposium will showcase small and large Pharma, regulatory partners and academia together building and broadening pharmaceutical sciences in Canada from discovery to recovery.”
We will be there at CREM Co’s booth to introduce our new platform for drug screening and drug discovery. Connect to CREM Co’s scientists to understand how we can help our industrial partners to discover effective drugs faster and cheaper. You can also get familiar with our novel methods for antimicrobial drug screening and antibiotic resistance characterization.
CREM Co Labs (CCL), based in Mississauga, Ontario, Canada, is a contracts research organization compliant with Good Laboratory Practice (GLP) regulations. It has extensive expertise in handling all major classes of microbial pathogens (bacteria, fungi, viruses and mycobacteria) using in vitro and in vivo assays. Its experience and expertise can be readily applied to antimicrobial drug screening and also to characterize the phenotypic and genotypic basis of resistant mutants.
To add to its capabilities, CCL has recently established the “Zebrafish Centre for Drug Discovery” which can use zebrafish as an animal model for drug screening and drug discovery.
Zebrafish have become an important model organism in drug discovery due to their genetic similarity to humans, ease of manipulation, and rapid development. Zebrafish embryos are also transparent, allowing for easy visualization of biological processes. Furthermore, the small size and high reproduction rate of zebrafish allow for high-throughput screening of multiple drugs simultaneously.
Zebrafish larvae can be employed in early-stage drug discovery to assess the safety and efficacy of New Chemical Entities (NCEs). They allow researchers to quickly screen a large number of compounds for potential therapeutic effects or toxicity.
Zebrafish larvae can also be employed to explore the potential repurposing of existing drugs for new therapeutic applications. By exposing zebrafish larvae to approved drugs that have been developed for different indications, researchers can assess their effects on specific disease models or biological processes. Zebrafish are now ranked by the U.S National Institutes of Health (NIH) as the third most important experimental modal in human medicine.
Overall, the use of zebrafish provides for a faster, economical and more reliable means of predicting the outcome of preclinical research.
Current Services:
- CCL’s Zebrafish Centre For Drug Discovery can perform acute toxicity, teratotoxicity (Developmental toxicity), neurotoxicity, cardiotoxicity, and multi-toxicity assays under GLP. Several standard operating procedures (SOPs) have already been developed following OECD 236 guideline and customized.
- Several disease models are available (customizable, if needed) for phenotyping and modeling of human disorders to perform drug efficacy assays. Some examples are Parkinson/Alzheimer, Intracerebral Hemorrhage (ICH)/Brain Microbleeds (BMB), Epilepsy, Stress, Anxiety etc.
- Testing different compound’s safety and efficacy to develop cosmetics can be tested on zebrafish larvae as using animals is not allowed in cosmetics industry. Zebrafish testing provides for a quick and cost-effective way of screening candidate compounds before safety and efficacy assessment on humans. Testing is also available for skin-lightening agents, anti-oxidants, etc.
CCL provides free consultation to biotech/pharma/cosmetics industry as well as to preclinical and clinical principal investigators. Please contact us to discuss about the details and performing your projects.